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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
apremilast (Otezla) is effective in reducing pruritus in adults over 18 years old with plaque 
psoriasis 
 
STUDY DESIGN: This review is based on three randomized controlled trials (RCTs) published 
in 2012, and 2015.  
 
DATA SOURCES: Three randomized controlled trials comparing the effectiveness of apremilast 
to a placebo in reducing pruritus in adults over 18 years old with plaque psoriasis, found using 
PubMed.  
 
OUTCOMES MEASURED: The outcome studied was improvement of the psoriatic plaques 
based on reduction in pruritus measured by the Pruritus Visual Analogue Scale (VAS) score 
and Psoriasis Area and Severity Index (PASI) score.  
 
RESULTS: Papp et al. (2012) showed a significant reduction in pruritus while using 30 mg 
of apremilast BID (p<0.0004). The study by Papp et al. (2015) showed that apremilast 
resulted in a significantly greater improvement compared to placebo, in reducing pruritus 
(p<0.0001).  The study by Paul et al. displayed significant improvements in pruritus when 
compared to the placebo (p<0.001)  
 
CONCLUSIONS: Results of all three studies demonstrate that 30mg of apremilist BID is 
effective in reducing pruritus in adults with plaque psoriasis. Each study showed 
improvement of pruritus with minimal side effects.  
 
KEYWORDS: Psoriasis, apremilast, otezla 
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INTRODUCTION  
Psoriasis is an immune-mediated dermatologic disease that presents most commonly as 
plaque psoriasis.1 Plaque psoriasis is characterized by thick, pruritic, silvery scales most 
commonly on the extensor surfaces of the body and the scalp.2 This paper evaluates three 
randomized controlled trials (RCTs) comparing the efficacy of apremilast (Otezla) in reducing 
pruritus in adults over 18 years old with plaque psoriasis to a placebo. 
Plaque psoriasis is relevant to patients and the physician assistant profession due to its 
prevalence and cost to the patients. Psoriasis affects 2% of the world’s population. It appears to 
have a genetic link, as 40% of patients with the condition have a family history of the disorder in 
first-degree relatives.3 About 40% of those with the condition can eventually develop psoriatic 
arthritis.4 Studies have estimated that the annual expenses of psoriasis can be as high as 
$25,796 per person.5 It is also thought that about $135 billion is spent annually in the 
United States for psoriasis.5 Approximately 2 million health visits per year occur due to this 
condition.4  
The exact cause of psoriasis is unknown, however, it is believed that it is due to 
hyperproliferation of cells, the immune system, and a genetic link. T-cells begin to attack healthy 
skin and there also is rapid cell turnover within a few days causing cells to rise and pile on the 
surface of the skin. There are several presentations such as plaque, inverse, guttate, pustular, and 
arthritic psoriasis. Plaque psoriasis most commonly presents as sharply defined, erythematous 
margins with a thick silvery scale that is often pruritic and can range from 1-10 cm in diameter.3 
Treatment depends on the type, location, and severity of the disease, however, avoiding 
excessive drying and keeping the area hydrated is essential in all cases.2 Topical glucocorticoid 
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steroids, vitamin D analogs, retinoids (methotrexate), or UV light therapy are commonly used 
treatment choices.  
The alternative treatment proposed and studied by this particular review is management 
with apremilast. Apremilast specifically inhibits PDE4, which is an enzyme that is found in the 
inflammatory cells and is important in the process of inflammation.6 When apremilast blocks the 
PDE4 enzyme, it down-regulates the inflammatory response. Apremilast can be offered as 
effective treatment with an acceptable safety and tolerability profile and improved convenience 
compared to current treatment choices.  
OBJECTIVE  
The objective of this selective EBM review is to determine whether or not apremilast 
is effective in reducing pruritus in adults over 18 years old with plaque psoriasis. 
METHODS  
All three studies used in this review required patients that were 18 years or older with 
moderate to severe plaque psoriasis. The intervention was the implementation of apremilast 
(Otezla) 30 mg taken twice daily. Comparisons were made between subjects who received the 
apremiliast to a group receiving a placebo. The specific outcome measured was the improvement 
of the psoriatic plaques based on the severity of plaques and the reduction in pruritus measured 
by the Pruritus Visual Analogue Scale (VAS) score and The Psoriasis Area and Severity 
Index (PASI) score. All three studies were randomized controlled trials (RCTs). 
 Keywords used when searching for articles consisted of: psoriasis, apremilast, and 
Otezla. All of the articles were published in English peer-reviewed journals. The articles chosen 
were researched by the author and obtained through PubMed. The articles were selected based 
on the type of studies, the relevance to the clinical question being asked, and that the outcomes 
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of the studies mattered to the patients (were POEMS). Inclusion criteria for selecting these 
articles included randomized controlled trials that directly benefited the patient and patients that 
have plaque psoriasis. Exclusion criteria included patients under 18 years old. The statistics that 
were utilized and reported included: p-value, relative benefit increase (RBI), absolute benefit 
increase (ABI), numbers needed to treat (NNT), relative risk increase (RRI), absolute risk 
increase (ARI), and numbers needed to harm (NNH). Table 1 displays the demographics and 
characteristics of the included studies.  
Table 1- Demographics & Characteristics of Included Studies 
Study Type # pts Age Inclusion Criteria Exclusion Criteria  W/D Intervention  
Papp, 
20126 
RCT  352 >18 
yo  
Pts >18 yo with 
moderate to severe 
plaque psoriasis for 
6 months or longer 
and were 
candidates for 
phototherapy or 
systemic therapy 
Pts with hx of or present 
significant disease, 
including TB, or HIV 
infection; had positive 
screening test for 
hepatitis B/C; were 
pregnant or 
breastfeeding; used 
topical therapy within 2 
wks or phototherapy 
/systemic within 4 wks 
18 Apremilast 
(Otezla) 10, 
20, 30mg BID 
vs. placebo 
group 
Papp, 
20157 
RCT, 
double
-blind 
844 >18 
yo 
Pts >18 yo with 
chronic plaque 
psoriasis and were 
candidates for 
phototherapy or 
systemic therapy 
Other significant or 
major uncontrolled 
disease, significant 
infection, active or hx of 
incomplete tx of TB, use 
of active topical agents 
for psoriasis within 2 
weeks, and prolonged 
sun or UV exposure  
53 Apremilast 
(Otezla) 30 
mg BID vs. 
placebo group 
Paul, 
20158 
RCT, 
double
-blind 
411 >18 
yo 
Adults aged >18 yo 
with chronic plaque 
psoriasis for >12 
months 
Significant cardiac, 
pulmonary, or 
immunological disease; 
active TB or hx of 
incomplete tx of TB, 
prolonged sun/UV 
exposure, use of 
biologics within 12-24 
wks, conventional 
systemic treatments 
within 4 wks or active 
topical treatments within 
2 weeks  
37 Apremilast 
(Otezla) 30 
mg BID vs. 
placebo group  
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OUTCOMES MEASURED  
 The outcomes measured in each of the studies focused on pruritus and the severity of the 
lesion, both, of which are important to the patient. In all three studies, the Visual Analog Scale 
(VAS) measured the change in pruritus over time. The Psoriasis Area and Severity Index (PASI) 
score measured the severity of the lesions. When PASI-75 is achieved, this means that there was 
a 75% decrease from the baseline score. These scores encompass how much area of the skin is 
involved and how severe the lesions are. A decrease in severity and the overall area that is 
affected by psoriasis influences pruritus.8  
RESULTS  
 The results were presented in dichotomous form in all three randomized controlled trials 
(RCTs) that were analyzed. Paul et al. & Papp et al. (2015) were also double blinded studies. All 
three studies assessed the effectiveness of apremilast (Otezla) 30 mg twice daily in the treatment 
for reducing pruritus in adults 18 years and older with plaque psoriasis. All three of the studies 
used a placebo group as the comparative group and randomized the patient population.  
 Papp et al. (2012), randomized patients to take either 10mg, 20mg, 30mg of apremilast or 
the placebo for a total of 24 weeks. However, for this review the 30mg vs. the placebo group will 
be focused on. There were a total of 88 patients receiving the placebo and 88 receiving 30mg of 
apremilast twice daily and both groups were the same at baseline. The apremilast 30mg was 
shown to provide rapid relief in pruritus during the initial 2 weeks, and was maintained 
throughout the entire 24 weeks, when compared to the placebo group. Patients were evaluated at 
16 and 24 weeks to assess any improvements. At week 16 the pruritus visual analog scale (VAS) 
scores were significantly lower with apremilast 30mg (p<0.004) compared to the placebo group. 
At 24 weeks, the mean percentage change from the baseline VAS scores was -41.5 (51.1) in 
 Carnes, Plaque Psoriasis and Apremilast 5 
those taking the apremilast. The PASI-75 at week 16 was achieved in 6% of patients taking the 
placebo and 41% of patients receiving 30mg of apremilast twice daily. The relative benefit 
increase (RBI) was calculated to be 5.38% and the absolute benefit increase (ABI) was 35%. 
This study determined that the number needed to treat (NNT) was 3 patients and the p-value was 
<0.0001.  
Papp et al. (2015), randomized 844 patients, 282 to receive the placebo and 562 to 
receive apremilast. After 16 weeks, approximately a 50% decrease in pruritus severity was noted 
in those receiving apremilast. The change in VAS score for the apremilast population was -31.5 
(32.43) and for the placebo group it was -7.3 (27.08). The VAS score was steady and showed 
minimal change at 32 weeks. There were 33% of apremilast patients who achieved PASI-75 
compared to 5.3% of placebo patients. (95% CI 23.1-32.5% for difference between apremilast 
and placebo of 27% p-value<0.0001). At 32 weeks, patients who originally started on apremilast 
at baseline were randomized to either stay on apremilast or switch to the placebo. Those that 
were randomized to stay on apremilast, 61% had PASI-75 response at the end of the study at 52 
weeks and 75.3% had 70% or more improvement in PASI score from baseline. The population 
who started to receive the placebo at 32 weeks, 83.1% lost PASI-75 response. The RBI was 
shown to be 5.25% and the ABI was 27.8%. NNT was determined to be 4 for those receiving 
30mg of apremilast.  
In the study by Paul et al., the placebo group of 137 patients was compared to 274 
patients who received apremilast 30mg twice daily. Mean improvements from baseline in 
pruritus and skin discomfort VAS score were significantly greater with apremilast (-33.5) vs. 
placebo (-12.2) (p-value <0.001), with a decrease in approximately 50% from baseline in the 
severity of pruritus and skin discomfort at week 16. At the conclusion of the study, 52 weeks, the 
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VAS score showed minimal, if any change from week 16. Analyzing PASI- 75 at week 16, 
demonstrated that it was achieved in 28.8% of the apremilast patients compared to 5.8% of those 
in the placebo group. Also at week 16, placebo patients switched to receive apremilast. At week 
32, those achieving PASI-50 were re-randomized to either start the placebo or continue with the 
apremilast. Most of the patients re-randomized to apremilast at week 32 had a PASI-50 response 
at the end of the study (80%). The RBI was shown to be 3.97% and the ABI was 23%. NNT was 
determined to be 5 for PASI-75. Table 2 displays the analysis of effectiveness of apremilast in 
reducing pruritus in plaque psoriasis for all three randomized controlled trials.  
Table 2. Analysis of effectiveness of apremilast in reducing pruritus in plaque psoriasis 
Study Placebo Apremilast RBI ABI NNT p-value/CI 
Papp 
(2012) 
6% 41% 5.83% 35% 3 <0.0001/95% 
Papp 
(2015) 
5.3% 33% 5.25% 27.8% 4 <0.0001/ 95% 
Paul (2015) 5.8% 28.8% 3.97% 23% 5 <0.001 
 
Treatment effects were analyzed and measured by assessing the adverse effects 
associated with taking apremilast. One of the most common adverse effects experienced in all 
three studies was that of diarrhea. Most cases of diarrhea were mild to moderate and usually 
resolved within 1 month. Table 3 shows the percentage of patients whom had diarrhea and the 
numbers needed to harm (NNH) for the selected studies.  
Table 3: Adverse Effects that result in NNH for the selected studies  
Study Placebo Apremilast RRI ARI NNH 
Papp (2012) 5% 14% 1.8% 9% 12 
Papp (2015) 7.1% 18.8% 1.65% 11.7% 9 
Paul (2015) 5.9% 15.8% 1.69% 10% 10 
 
DISCUSSION  
 Since plaque psoriasis affects so many people, it is imperative to discuss the efficacy, 
safety, and realistic application of apremilast as treatment. Apremilast is an oral medication that 
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is slowly titrated from 10mg in the morning (can be taken on an empty stomach) on Day 1, to 
eventually 30mg twice daily on day 6.9 Contraindications include hypersensitivity to apremilast 
or any ingredient used to create it. In regards to safety, neuropsychiatric effects such as 
depression and suicide ideation have been reported, thus it is advised to use precaution in 
patients who have a past medical history of depression. Unexplained weight loss has been seen 
as well and apremilast should be discontinued if significant weight loss occurs. It is also advised 
to use with caution in those with renal impairment and dosage reduction is recommended.10 
Apremilast is considered to be a category C medication and has risks and unknowns during 
pregnancy.  
Current pricing in the US is $3,103.46 for 60 tablets of 30mg (1 month’s supply).10 There 
is currently no generic for this medication. Apremilast is delivered by a specialty pharmacy, that 
may need to receive prior authorization from the patient’s insurance company before they send 
the prescription.9 Apremilast is not only used in plaque psoriasis, but is also being prescribed as 
medical therapy for psoriatic arthritis.  
All three RCTs showed limitations within their study. Papp et al. (2012) only had 24 
weeks worth of data to analyze, while Papp et al. (2015) and Paul et al. had 52 weeks. All three 
studies lacked long term data on efficacy and safety. The studies also enrolled a number of 
obese, white men, thus the results may not be generalizable to a diverse population, other races, 
non-plaque psoriasis, or other co-morbidities.  
CONCLUSION 
 The three selected studies for this systematic review demonstrated that apremilast 
(Otezla) is effective in reducing pruritus in adults over 18 years old suffering from plaque 
psoriasis. The positive changes in patients’ VAS score and the amount of patients achieving 
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PASI-75 when taking 30mg of apremilast twice daily, demonstrates that it is a very useful 
therapeutic intervention for medical providers to consider when an adult patient is complaining 
of pruritus due to plaque psoriasis. It is also important to remember that the side effect profile 
was low in all three studies and that most symptoms resolved within 1 month, thus most patients 
tolerated the medication and continued with treatment. While evidence provided in these studies 
supports the use of apremilast 30 mg BID to reduce pruritus, further suggestions to improve 
studies would be to research the efficacy in patients with a more diverse background, and not 
limited to obese, white men. The duration of treatment was also short term, thus warranting 
additional studies to evaluate the long-term effects of apremilast on plaque psoriasis symptom 
improvement.
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